CAMBRIDGE, Mass., Nov. 1, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that updated data from its ongoing Phase 1 clinical trial evaluating BLU-285 for the treatment of advanced systemic mastocytosis (SM) will be presented in an oral presentation during the Plenary Scientific Session of the 59^thAmerican Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia, December 9-12, 2017.  The Plenary Scientific Session honors the top six abstracts among 6,000 abstract submissions to the meeting, as determined by the ASH Program Committee.

Presentation Title: Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)
Session Title: Plenary Scientific Session
Session Date & Time: Sunday, December 10, 2017 from 2:00-4:00 p.m. ET
Abstract Number: 2
Location: Georgia World Congress Center, Bldg C – Lvl 1 – Hall C2–C3

The accepted abstract is available online on the ASH website at http://www.hematology.org/Annual-Meeting/. 

Conference Call and Webcast Information

Blueprint Medicines will host a conference call and webcast on Monday, December 11, 2017 at 6:00 a.m. ET to discuss the updated BLU-285 clinical data presented at ASH. To participate in the conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international) and refer to conference ID 4072589. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be available approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-updated-data-from-ongoing-phase-1-clinical-trial-of-blu-285-in-patients-with-advanced-systemic-mastocytosis-in-plenary-scientific-session-at-59th-ash-annual-meeting-and-exposition-300547305.html

SOURCE Blueprint Medicines

Kristin Hodous, 617 714 6674, khodous@blueprintmedicines.com; Jim Baker, 617 844 8236, jbaker@blueprintmedicines.com